A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

NCT ID: NCT04317885

Last Updated: 2025-05-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-05
• Study Completion Date: 2023-12-30

Brief Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients

Detailed Description

This study plans to enroll 25 patients to assess the safety and efficacy of C-CAR039. Subjects who meet the eligibility criteria will receive a single dose of C-CAR039 injection.

The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Bridging (if needed), Baseline, lymphodepletion, C-CAR039 infusion, and Follow-up Visit.

Conditions

Non-Hodgkin's B-cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Prizloncabtagene Autoleucel

Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion

Group Type: EXPERIMENTAL

Prizloncabtagene Autoleucel

Intervention Type: BIOLOGICAL

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Interventions

Prizloncabtagene Autoleucel

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Intervention Type: BIOLOGICAL

Other Intervention Names

C-CAR039

Eligibility Criteria

Inclusion Criteria

• 1. Volunteered to participate in this study and signed informed consent
• 2. Age 18-75 years old, male or female
• 3. CD19 or CD20 positive DLBCL (including PMBCL and tFL), FL and MCL confirmed by cytology or histology according to WHO2016 criteria. For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause should be recorded.
• 4. Relapsed or refractory disease after ≥ 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT)
• 5. At least one measurable lesion (LDi ≥ 1.5 cm);
• 6. At least two weeks from last treatment (radiation, chemotherapy, mAb, etc) to apheresis;
• 7. LVEF≥ 50% (ECHO)
• 8. No active pulmonary infections, normal or mild impaired pulmonary function and SpO2≥92%
• 9. Laboratory criteria: ANC≥1.0×109/L; Platelets≥50×109/L; Serum total bilirubin ≤1.5x ULN; Creatinine≤ ULN; AST and ALT≤3x ULN
• 10. No contraindications of apheresis;
• 11. Expected survival ≥ 3months
• 12. ECOG score 0 or 1

Exclusion Criteria

• 1. Have a history of allergy to cellular products;
• 2. According to the NYHA cardiac function grading standards, patients with grade III or IV cardiac dysfunction;
• 3. A history of craniocerebral trauma, disturbance of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.;
• 4. Patients with central nervous system involvement;
• 5. Patients with autoimmune diseases, immunodeficiency or other conditions requiring immunosuppressive therapy;
• 6. Received allogeneic hematopoietic stem cell transplantation before;
• 7. Previous use of any CAR T cell product or other genetically modified T cell therapy;
• 8. Autologous stem cell transplantation within 6 weeks before infusion;
• 9. Severe active infections (except for simple urinary tract infections, bacterial pharyngitis), or currently undergoing intravenous infusion of antibiotics. However, prophylactic antibiotic, antiviral and antifungal infection treatments are permissible;
• 10. Live vaccination within 4 weeks prior to apheresis;
• 11. People infected with HIV, HBV, HCV and TPPA/RPR, and carriers with HBV;
• 12. A history of alcohol abuse, drug use or mental illness;
• 13. Subjects who are not sterilized and have any of the following conditions:

1. are pregnant/lactating; or

2. planned pregnancy during the trial; or

3. being fertile and unable to use effective contraception;

• 14. Severe hypersensitivity to fludarabine or cyclophosphamide;
• 15. A history of other primary cancers other than the following:

1. Non-melanoma tumors such as basal cell carcinoma of the skin that are cured by excision

2. Cured in situ cancers such as cervical, bladder, or breast cancer

• 16. The investigators consider that the subject has other conditions that are not suitable for this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai AbelZeta Ltd.

INDUSTRY

Sponsor Role: collaborator

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Aibin Liang，MD，Ph.D.

Director, Department of Hematology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Aibin Liang, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Shanghai Tongji Hospital, Tongji University School of Medicine

Locations

Shanghai Tongji Hospital, Tongji University School of Medicine

Shanghai, Shanghai Municipality, China

Countries

China

References

Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D, Huang J, Yao X, Zhang Y, Li L, Zhao J, Zhu K, Li J, Zheng C, Lan L, Wan H, Yao Y, Zhang H, Zhou D, Jin J, Liang A. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1526-1535. doi: 10.1182/blood.2024026401.

Reference Type: DERIVED

PMID: 39813680 (View on PubMed)

Other Identifiers

0702-015

Identifier Type: -

Identifier Source: org_study_id